-
Zidesamtinib Demonstrates a High Objective Response Rate in TKI-Naïve Patients with Advanced ROS1-Positive NSCLC
Researcher Alexander Drilon, MD, said at a median follow-up duration of 15.2 months, the objective response rate was 94%, and the complete response rate was 15%.
More News from #WCLC26
-
Overall Survival Benefit Seen in Interim Analysis of ARTEMIS-008 Signals Rapidly Expanding Landscape of ADC-Based Therapies in Small Cell Lung Cancer
Prof. Jie Wang, MD, said risvutatug rezetecan, a B7-H3-directed antibody-drug conjugate, demonstrated an overall survival benefit compared with topotecan in patients with relapsed SCLC.
-
Adjuvant Osimertinib Demonstrates Sustained OS Benefit in Resected EGFR-Mutated NSCLC
Presented by Roy S. Herbst, MD, PhD, an exploratory analysis of the global phase III ADAURA trial reveals sustained overall survival benefit—over the longest follow-up to date—in resected EGFR-mutated NSCLC.
